PE20200739A1 - Pirrolopirimidinas como potenciadores de cftr - Google Patents
Pirrolopirimidinas como potenciadores de cftrInfo
- Publication number
- PE20200739A1 PE20200739A1 PE2019001045A PE2019001045A PE20200739A1 PE 20200739 A1 PE20200739 A1 PE 20200739A1 PE 2019001045 A PE2019001045 A PE 2019001045A PE 2019001045 A PE2019001045 A PE 2019001045A PE 20200739 A1 PE20200739 A1 PE 20200739A1
- Authority
- PE
- Peru
- Prior art keywords
- group
- alkyl
- cftr
- carbonitrile
- pyrrolo
- Prior art date
Links
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 abstract 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- IOWDAFLMNLDYIA-GFCCVEGCSA-N 4-amino-5-[2-(difluoromethyl)pyrimidin-5-yl]-7-[(1R)-1-[1-(2-fluorophenyl)pyrazol-4-yl]ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)F)C#N)[C@H](C)C=1C=NN(C=1)C1=C(C=CC=C1)F IOWDAFLMNLDYIA-GFCCVEGCSA-N 0.000 abstract 1
- IOWDAFLMNLDYIA-LBPRGKRZSA-N 4-amino-5-[2-(difluoromethyl)pyrimidin-5-yl]-7-[(1S)-1-[1-(2-fluorophenyl)pyrazol-4-yl]ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)F)C#N)[C@@H](C)C=1C=NN(C=1)C1=C(C=CC=C1)F IOWDAFLMNLDYIA-LBPRGKRZSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
LSe refiere a un compuesto de formula (I) o una sal farmaceuticamente aceptable del mismo, en donde W es fenilo, que esta opcionalmente fusionado con un cicloalquilo de cinco a seis miembros o un heterocicloalquilo de cinco a seis miembros, entre otros; Y es un heteroarilo de cinco miembros que comprende uno, dos, tres o cuatro heteroatomos seleccionados del grupo que consiste en N, O y S(O)n; Z se selecciona del grupo que consiste en fenilo, alquilo C1-C6, cicloalquilo C3-C7, entre otros; R1a y R1b se seleccionan cada uno independientemente del grupo que consiste en -H, -OH, halo, alquilo C1-C6, entre otros; R2 se selecciona del grupo que consiste en -H, halo, -CN, entre otros; R3 y R4 se seleccionan del grupo que consiste en -H, alquilo C1-C6 y haloalquilo C1-C6. Son compuestos preferidos 4-amino-5-[2-(difluorometil)pirimidin-5-il]-7-{(1S)-1-[1-(2-fluorofenil)-1H-pirazol-4-il]etil}-7H-pirrolo[2,3-d]pirimidina-6-carbonitrilo, 4-amino-5-[2-(difluorometil)pirimidin-5-il]-7-{(1R)-1-[1-(2-fluorofenil)-1H-pirazol-4-il]etil}-7H-pirrolo[2,3-d]pirimidina-6-carbonitrilo, entre otros. Dichos compuestos son potenciadores del Regulador de Conductancia Transmembrana de la Fibrosis Quistica (CFTR), siendo utiles en el tratamiento de la fibrosis quistica, el asma, la bronquiectasia, la enfermedad pulmonar obstructiva cronica (EPOC). Tambien se refiere a composiciones farmaceuticas que comprenden dicho compuesto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662423919P | 2016-11-18 | 2016-11-18 | |
PCT/US2017/062148 WO2018094137A1 (en) | 2016-11-18 | 2017-11-17 | Pyrrolopyrimidines as cftr potentiators |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20200739A1 true PE20200739A1 (es) | 2020-07-24 |
Family
ID=62144793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019001045A PE20200739A1 (es) | 2016-11-18 | 2017-11-17 | Pirrolopirimidinas como potenciadores de cftr |
Country Status (21)
Country | Link |
---|---|
US (5) | US10301315B2 (es) |
EP (1) | EP3541390B1 (es) |
JP (3) | JP6978507B2 (es) |
KR (2) | KR20230146104A (es) |
CN (2) | CN110337294B (es) |
AU (2) | AU2017362350B2 (es) |
BR (1) | BR112019010167A2 (es) |
CA (1) | CA3044050A1 (es) |
CL (1) | CL2019001334A1 (es) |
CO (1) | CO2019005993A2 (es) |
CR (1) | CR20190292A (es) |
DO (1) | DOP2019000126A (es) |
EC (1) | ECSP19043120A (es) |
IL (2) | IL296279A (es) |
MX (2) | MX2021012639A (es) |
PE (1) | PE20200739A1 (es) |
PH (1) | PH12019501098A1 (es) |
RU (2) | RU2021129721A (es) |
SG (1) | SG10202106949XA (es) |
UA (1) | UA125400C2 (es) |
WO (1) | WO2018094137A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2800565T (pt) | 2012-01-06 | 2020-04-29 | Scripps Research Inst | Compostos de carbamato e processos para a sua preparação e utilização |
PL3203840T3 (pl) | 2014-10-06 | 2021-01-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
US20180369209A1 (en) * | 2015-12-22 | 2018-12-27 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
WO2018064632A1 (en) | 2016-09-30 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
SG10202106949XA (en) * | 2016-11-18 | 2021-07-29 | Cystic Fibrosis Found | Pyrrolopyrimidines as cftr potentiators |
WO2018107100A1 (en) | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
JP7150721B2 (ja) | 2016-12-16 | 2022-10-11 | システィック・ファイブロシス・ファンデーション | Cftr増強物質としての二環式ヘテロアリール誘導体 |
BR112019025801A2 (pt) | 2017-06-08 | 2020-07-07 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2019028228A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS |
WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
AU2018380426B2 (en) | 2017-12-08 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
PT3752510T (pt) | 2018-02-15 | 2023-03-15 | Vertex Pharma | Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
AU2020290094B2 (en) * | 2019-06-10 | 2024-01-18 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis |
JP2022541178A (ja) | 2019-07-15 | 2022-09-22 | ノバルティス アーゲー | (s)-3-アミノ-6-メトキシ-n-(3,3,3-トリフルオロ-2-ヒドロキシ-2-メチルプロピル)-5-(トリフルオロメチル)ピコリンアミド製剤 |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
WO2021030552A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
CN111138439B (zh) * | 2020-01-17 | 2021-06-25 | 厦门大学 | 氟代吡咯并嘧啶类化合物及其制备方法和应用 |
WO2021176049A1 (en) | 2020-03-06 | 2021-09-10 | Bayer Aktiengesellschaft | Pyrazolopyrazines acting on cancers via inhibition of cdk12 |
JP2023538125A (ja) | 2020-08-20 | 2023-09-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 粘液過剰分泌を特徴とする呼吸器疾患を処置するための方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013676A1 (en) * | 1992-12-17 | 1994-06-23 | Pfizer Inc. | Pyrrolopyrimidines as crf antagonists |
IL149462A0 (en) * | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
WO2002096867A2 (en) * | 2001-05-30 | 2002-12-05 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
US20050008640A1 (en) * | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
CA2553724A1 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
CN101389630A (zh) * | 2005-12-29 | 2009-03-18 | 艾博特公司 | 蛋白激酶抑制剂 |
KR20090007319A (ko) * | 2006-03-11 | 2009-01-16 | 베르날리스 (알 앤드 디) 리미티드 | Hsp90 억제제로서 사용되는 피롤로피리미딘 유도체 |
CA2647391C (en) * | 2006-04-04 | 2015-12-29 | The Regents Of The University Of California | Kinase antagonists |
JP2011503103A (ja) * | 2007-11-07 | 2011-01-27 | フォールドアールエックス ファーマシューティカルズ インコーポレーティッド | タンパク質輸送の調節方法 |
JP5452617B2 (ja) * | 2009-01-08 | 2014-03-26 | キュリス,インコーポレイテッド | 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター |
US20130123281A1 (en) | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules |
US8828998B2 (en) * | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
WO2014060431A1 (en) * | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
WO2015091532A1 (en) | 2013-12-19 | 2015-06-25 | Almirall, S.A. | Pyrrolopyrimidine derivatives as pi3k inhibitors |
SG10202106949XA (en) * | 2016-11-18 | 2021-07-29 | Cystic Fibrosis Found | Pyrrolopyrimidines as cftr potentiators |
-
2017
- 2017-11-17 SG SG10202106949XA patent/SG10202106949XA/en unknown
- 2017-11-17 KR KR1020237033420A patent/KR20230146104A/ko active Application Filing
- 2017-11-17 KR KR1020197017510A patent/KR102585398B1/ko active IP Right Grant
- 2017-11-17 RU RU2021129721A patent/RU2021129721A/ru unknown
- 2017-11-17 CN CN201780083801.0A patent/CN110337294B/zh active Active
- 2017-11-17 MX MX2021012639A patent/MX2021012639A/es unknown
- 2017-11-17 JP JP2019547579A patent/JP6978507B2/ja active Active
- 2017-11-17 MX MX2019005822A patent/MX2019005822A/es unknown
- 2017-11-17 RU RU2019118623A patent/RU2757457C2/ru active
- 2017-11-17 CR CR20190292A patent/CR20190292A/es unknown
- 2017-11-17 UA UAA201906838A patent/UA125400C2/uk unknown
- 2017-11-17 IL IL296279A patent/IL296279A/en unknown
- 2017-11-17 CA CA3044050A patent/CA3044050A1/en active Pending
- 2017-11-17 US US15/815,809 patent/US10301315B2/en active Active
- 2017-11-17 PE PE2019001045A patent/PE20200739A1/es unknown
- 2017-11-17 BR BR112019010167A patent/BR112019010167A2/pt active Search and Examination
- 2017-11-17 EP EP17872726.9A patent/EP3541390B1/en active Active
- 2017-11-17 WO PCT/US2017/062148 patent/WO2018094137A1/en active Application Filing
- 2017-11-17 CN CN202211239693.0A patent/CN115850268A/zh active Pending
- 2017-11-17 AU AU2017362350A patent/AU2017362350B2/en active Active
-
2019
- 2019-04-05 US US16/377,005 patent/US10494374B2/en active Active
- 2019-05-15 IL IL266668A patent/IL266668B2/en unknown
- 2019-05-16 PH PH12019501098A patent/PH12019501098A1/en unknown
- 2019-05-16 CL CL2019001334A patent/CL2019001334A1/es unknown
- 2019-05-17 DO DO2019000126A patent/DOP2019000126A/es unknown
- 2019-06-07 CO CONC2019/0005993A patent/CO2019005993A2/es unknown
- 2019-06-17 EC ECSENADI201943120A patent/ECSP19043120A/es unknown
- 2019-09-20 US US16/578,277 patent/US20200017512A1/en not_active Abandoned
-
2021
- 2021-02-18 US US17/179,062 patent/US20210171534A1/en not_active Abandoned
- 2021-11-10 JP JP2021183048A patent/JP7360434B2/ja active Active
-
2022
- 2022-03-16 AU AU2022201816A patent/AU2022201816B2/en active Active
-
2023
- 2023-04-13 US US18/134,455 patent/US20230250100A1/en active Pending
- 2023-09-29 JP JP2023169299A patent/JP2023182694A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20200739A1 (es) | Pirrolopirimidinas como potenciadores de cftr | |
ECSP18032223A (es) | PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO DE USO | |
CL2017003445A1 (es) | Formas solidas y formulaciones de compuestos de imidazopirazina. | |
CY1119771T1 (el) | Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak | |
CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
CO2017005421A2 (es) | Cromanos sustituidos y métodos para su uso | |
DOP2018000020A (es) | Tricíclicos sustituidos y método para usarlos | |
CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
PE20161475A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
NI201400151A (es) | 7H - PIRROLO [ 2, 3 - d ] PIRIMIDINAS 4 - ( AMINO - SUBSTITUIDAS ) NOVEDOSAS COMO INHIBIDORES DE LRRK2. | |
SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
PE20161427A1 (es) | Inhibidores heteroarilo de syk | |
PE20160869A1 (es) | Derivados novedosos de amino pirimidina | |
EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
CL2013002877A1 (es) | Compuestos derivados de 2-aminopirimidina o una de sus sales, tautomeros o solvatos farmaceuticamente aceptables, moduladores de los receptores tlr7 y/o tlr8; composicion farmaceutica que los comprende, utiles para el tratamiento de infecciones viricas tales como vhb o vhc | |
EA201691484A1 (ru) | Соли и твердая форма ингибитора btk | |
PE20130602A1 (es) | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a | |
BR112015012693A2 (pt) | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
CO2019004190A2 (es) | Formulaciones liposomales para uso en el tratamiento del cáncer | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы |